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Abstract Tumor necrosis factor K and fMLP can activate a
broad range of cellular functions in neutrophils adherent to
biological surfaces. These functions are mediated by integrins
and involve the activation of tyrosine kinases. Here, we report
that Pyk2, a member of the focal adhesion kinase family, was
present in human neutrophils and was rapidly phosphorylated and
activated following tumor necrosis factor K and fMLP stimula-
tion in an adhesion-dependent manner. Tyrosine phosphorylation
of Pyk2 was attenuated by L2 integrin blocking with specific
antibodies. The tyrosine phosphorylation of Pyk2 was down-
stream of protein kinases Lyn, Syk and protein kinase C and
cytoskeletal organization. The activation of Pyk2 may play a
role in adhesion/cytoskeleton-associated neutrophils function.
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1. Introduction
The ligation of integrins on neutrophils (PMN) initiates a
cascade of biochemical events that results in reorganization of
the cytoskeleton, cell spreading over the adhesive surface and
the release of reactive oxygen intermediates (ROI) and granule
constituents [1]. Tyrosine phosphorylation of proteins plays a
critical role in this signal transduction pathway [1^3]. Among
the signal transduction molecules that are tyrosine-phospho-
rylated are paxillin [4,5], the focal adhesion kinase FAK [5^7],
the mitogen activated protein kinase (MAPK) [8], the protein-
tyrosine kinases (PTK) p58cÿfgr [9], Lyn [10], Syk [11], phos-
pholipase C-Q2 [12] and the proto-oncogene product Vav [13].
The phosphorylation of most of these molecules is commonly
accompanied by the enhancement of their biological activities
thereby activating a variety of cellular functions. A rapidly
growing body of evidence has established that src family
PTKs play a pivotal role in integrin signaling in human
PMN. The activation of src-like kinases p58cÿfgr and p53/
56lyn in PMN is associated with integrin signaling [9,10]. In-
hibition of this family of PTKs with a speci¢c inhibitor PP1
blocked the integrin-dependent activation of PMN function
by TNF [14]. More directly, PMN from fgr3=3hck3=3 dou-
ble-mutant mice neither spread nor produce ROI on plasma
and ECM proteins, the leukocyte integrin counter-receptor
ICAM-1 and anti-integrin Ab (antibody)-coated surfaces [15].
In addition, p72syk is also activated by PMN integrin signals.
Upon activation, p72syk forms multimolecular complexes with
several tyrosine-phosphorylated proteins and tyrosine kinases
p58cÿfgr and p53/56lyn [11], indicating that p72syk may take
part in integrin signaling in PMN.
In the current models of integrin signaling, another family
of PTKs known as FAK occupies a more important position
[3,16^19]. Integrin ligation induces the activation of FAK and
their aggregation with integrins and cytoskeletal proteins at
focal contacts. Thereafter, FAK transfers the integrin signals
into diverse signaling pathways including those of PI-3 kinase,
MAP kinase and cytoskeletal rearrangement [20,21]. FAK has
been detected in the lysates of human PMN [5^7], but it does
not appear to be activated by cell adhesion [5,7], suggesting
that FAK has a less certain role in integrin signaling in PMN
[19]. Recently, Pyk2 was identi¢ed as another member of the
FAK family of PTKs [22^24]. Pyk2 (also called RAFTK for
related adhesion focal tyrosine kinase, CAKL for cell adhe-
sion kinase L, CADTK and FAK2) is a cytoplasmic protein-
tyrosine kinase and, like FAK, couples to several signaling
pathways which regulate a variety of cellular functions
[22,25,26]. Pyk2 is expressed in hematopoietic cells including
primary bone marrow megakaryocytes [24,27,28], monocyte
macrophages [29,30], platelets [31], mast cells [32] and T-
[33^35] and B-cells [36]. The stimulation of many di¡erent
cell surface receptors results in the tyrosine phosphorylation
and activation of Pyk2 [22,24^26,37,38]. These stimuli include
carbachol acting through nicotinic acetylcholine receptors,
stress signals, membrane depolarization, cytokines and mole-
cules that activate G-protein-coupled receptors. Recently,
Pyk2 was found to be tyrosine-phosphorylated after integrin
or immune receptor activation [27,33^36]. Pyk2 is also acti-
vated by addition of the calcium ionophore A23187 and
PMA, suggesting that the activation of Pyk2 is downstream
of the increase in intracellular calcium and the activation of
protein kinase C (PKC) [22,28]. At the present time, no stud-
ies have reported on the presence or activation of Pyk2 in
human PMN.
Here we report that Pyk2 was present in human PMN.
Stimulation of the cells with tumor necrosis factor K
(TNFK) or the chemotactic peptide fMLP induced the tyro-
sine phosphorylation of Pyk2 which was mainly associated
with a Triton X-100 insoluble cytoskeletal fraction in a L2
integrin-dependent manner. By using di¡erent inhibitors, we
also demonstrated that the phosphorylation of Pyk2 was a
downstream event of the activation of p53/56lyn, p72syk,
PKC and rearrangement of the cytoskeleton. These data sug-
gest that Pyk2 may function in signaling events associated
with PMN adhesion and cytoskeletal rearrangement.
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2. Materials and methods
2.1. Materials
Fibrinogen was obtained from Gibco BRL Products (Gaithersburg,
MD, USA) and recombinant human TNFK from Pepro Tech (Rocky
Hill, NJ, USA). Protein Assay (Bradford) and sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE) reagents were pur-
chased from Bio-Rad Laboratories (Melville, NY, USA), Immoblot
PVDF (polyvinylidene di£uoride) transfer membranes from Millipore
Corporation (Bedford, MA, USA), protease inhibitors from Boehr-
inger Mannheim (Mannheim, Germany), the enhanced chemilumin-
escence (ECL) Western blotting detection reagents from Amersham
Life Science (Arlington Heights, IL, USA) and protein A-bound Tris-
acryl beads from Pierce (Rockford, IL, USA). Abs used in this study
were obtained from the following sources: monoclonal Ab (mAb)
SZ21 (IgG1, anti-human CD61, L3 integrin subunit) and mAb Lia1/
2 (IgG1, anti-human CD29, L1 integrin subunit) from Immunotech
(Westbrook, ME, USA), mAbs L130 (IgG1, anti-human CD18, L2
integrin subunit), G25.2 (IgG2a, anti-CD11a), D12 (IgG2a, anti-
CD11b) and SHCL-3 (IgG2b, anti-CD11c) from Becton Dickinson
(San Jose, CA, USA), mAb IB4 (IgG2b, anti-CD18) from Dr S.D.
Wright (Merk Research Laboratories, Rathway, NJ, USA), goat anti-
Pyk2 polyclonal Ab, horseradish peroxidase (HRP)-conjugated rabbit
anti-goat IgG, anti-phosphotyrosine mAb PY20 and HRP-conjugated
PY20 from Santa Cruz Biotechnology (Santa Cruz, CA, USA). In-
hibitors for PTKs (genistein), src kinases (PP1), syk kinase (piceatan-
nol), PKC (bisindolylmaleimide I or Go«6850 and staurosporine), PI-3
kinase (wortmannin) or actin polymerization (cytochalasin B) were
purchased from Calbiochem (La Jolla, CA, USA). All other reagents
were purchased from Sigma BioScience (St. Louis, MO, USA).
2.2. PMN isolation
PMN were isolated from peripheral human venous blood of healthy
volunteers using the method of dextran sedimentation and centrifuga-
tion over Ficoll-Paque as previously reported [14]. The cells were
¢nally washed once in phosphate-bu¡ered saline (PBS) and resus-
pended in KRPg (Krebs-Ringer phosphate bu¡er with glucose: 145
mM NaCl, 4.86 mM KCl, 1.22 mM MgSO4, 5.7 mM Na2HPO4, 0.54
mM CaCl2 and 5.5 mM glucose, pH 7.4) at a density of 107 cells/ml.
2.3. PMN incubation and lysate preparation
In some experiments, PMN were pretreated with 10 Wg/ml of the
Abs indicated in Section 3 for 45 min on ice with gentle mixing every
5 min. Plastic tissue culture 12 well plates were pre-coated with ¢bri-
nogen (250 Wg/ml in PBS, 500 Wl/well) at 4‡C overnight followed by
four washes in PBS. The cells were allowed to settle onto the pre-
coated surfaces and to equilibrate to 37‡C by incubating in the ¢bri-
nogen-coated plates (0.6 ml/well) or shaking in polypropylene round
bottom tubes in a 37‡C water bath for 10 min before stimulation.
When necessary, genistein (50 WM), PP1 (5 WM), piceatannol (5 WM),
cytochalasin B (CB, 5 Wg/ml), wortmannin (10 nM), staurosporine
(100 nM) or Go«6850 (50 nM) were added to the cells at the same
time as they were dispensed into the wells. The cells were incubated in
the absence or presence of TNFK (20 ng/ml) or fMLP (100 nM) for
the times indicated in Section 3. The cells incubated in tubes were then
transferred to Eppendor¡ tubes and spun down by microfuging for
10 s and the incubation media in the wells were removed by aspira-
tion. Cytosolic proteins were removed from the pelleted cells and the
cells adherent to the wells by treating with CSK bu¡er (25 mM
PIPES, pH 6.9, 4 M glycerol, 1 mM EGTA, 0.2% Triton X-100,
5 Wg/ml of pepstatin and leupeptin, 10 WM phenylarsine oxide,
5 mM NaF, 1 mM dithiothreitol, 1 mM phenylmethylsulfonyl £uo-
ride, 1 mM EDTA, 100 WM sodium vanadate and 2.5 mM diisopropyl
£uorophosphate) for 4 min at room temperature followed by centrif-
ugation at 2000Ug for 4 min as previously described [39]. The result-
ing Triton X-100 insoluble cytoskeletal fractions were further solubi-
lized by boiling in SDS-PAGE sample bu¡er. In some experiments,
the cells were directly solubilized in RIPA bu¡er [10,11,39] or SDS-
PAGE sample bu¡er.
2.4. Immunoprecipitation and Western blotting
Protein concentrations in the lysates, determined by the Bio-Rad
Bradford Protein Assay method according to the manufacturer’s in-
structions, were adjusted by appropriately diluting with SDS-PAGE
sample bu¡er. Equal volumes (containing 150 Wg of proteins) of each
lysate were diluted eight times with Tris-bu¡ered saline (TBS: 25 mM
Tris-HCl, pH 7.5, 150 mM NaCl). Triton X-100 was added to a ¢nal
concentration of 2% (v/v) and pre-cleared by rotating with 30 Wl of a
slurry of protein A-bound Trisacryl beads for 1 h at 4‡C. The beads
were then removed by microfuging for 2 min and the supernatants
were precipitated with goat anti-Pyk2 Ab (2 Wg/sample) or anti-PY
mAb PY20 (5 Wg/sample) immobilized on protein A-Trisacryl beads
by rotating for 5 h at 4‡C. After intensively washing with TBS/2%
Triton X-100 supplemented with 1/8 volume of SDS-PAGE sample
bu¡er, the precipitates were eluted by boiling in SDS-PAGE sample
bu¡er and separated by SDS-PAGE and transferred onto PVDF
membranes. The membranes were detected by Western blotting using
HRP-conjugated anti-PY mAb PY20 or goat anti-Pyk2 followed by
HRP-conjugated rabbit anti-goat IgG and visualized by ECL re-
agents. Thereafter, the overlaid Ab was stripped with a stripping
bu¡er as instructed by the manufacturer of ECL reagents and the
membrane was re-blotted for the protein of Pyk2 using goat anti-
Pyk2 Ab followed by an HRP-conjugated rabbit anti goat IgG and
ECL reagents [14,39].
Fig. 1. Pyk2 is expressed in human PMN and its phosphorylated
form is mainly associated with a Triton X-100 insoluble cytoskeletal
fraction. (A) Human PMN were lysed with SDS-PAGE sample
bu¡er immediately after isolation and the indicated amounts of pro-
tein were loaded and separated by SDS-PAGE. The protein was de-
tected by Western blotting (WB) using a goat anti-Pyk2 Ab fol-
lowed by an HRP-conjugated rabbit anti-goat IgG. The bound Abs
were visualized by using ECL reagents as describe in Section 2. (B)
Fibrinogen adherent PMN were stimulated with TNF or fMLP for
5 min. At the end of each incubation, the cells were either directly
solubilized in RIPA bu¡er followed by centrifugation at 12 000Ug
for 15 min to provide a RIPA soluble fraction (the right three
lanes) or treated with a Triton X-100 containing bu¡er (CSK) fol-
lowed by centrifugation at 2000Ug for 4 min to provide a Triton
X-100 insoluble pellet as the cytoskeletal fraction (the left three
lanes) which were further solubilized in boiling SDS-PAGE sample
bu¡er. The lysates were diluted eight times and immunoprecipitated
(IP) using the anti-Pyk2 Ab immobilized on protein A-Trisacryl
beads. The precipitates were analyzed by Western blotting (WB) us-
ing HRP-conjugated anti-phosphotyrosine mAb PY20 (upper panel).
The membranes were stripped and re-blotted for Pyk2 protein (low-
er panel) as described in A. This ¢gure represents one of four inde-
pendent experiments with similar results.
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3. Results
3.1. Pyk2 is expressed by human PMN and TNF or fMLP
induces its tyrosine phosphorylation when associated with a
cytoskeletal fraction
It has long been noted that cellular proteins with molecular
weights of ~115^120 kDa are phosphorylated on tyrosine res-
idues following L2 integrin activation in human PMN
[9,10,14,40,41]. Since Pyk2 is a ~115 kDa molecule which is
involved in integrin signaling in megakaryocytes, platelets and
T- and B-cells [27,35,36], we examined whether Pyk2 was ex-
pressed and tyrosine-phosphorylated in human PMN. By im-
munoblotting, the Pyk2 PTK was easily detectable in human
PMN even when as low as 5 Wg of lysate proteins were loaded
on a single lane (Fig. 1A), suggesting that human PMN ex-
press large amounts of this enzyme. However, when assays
were carried out to assess the tyrosine phosphorylation of
this kinase in PMN stimulated without or with TNF or
fMLP and lysed with RIPA bu¡er, no signi¢cant enhance-
ment of tyrosine phosphorylation was detected (the right three
lanes in the upper panel of Fig. 1B). Since RIPA bu¡er can
extract most of the cytosolic proteins but cannot solubilize
those tightly associated with the cytoskeleton, while Pyk2 is
found associated with cytoskeletal proteins in several cell lines
[28,42,43], we therefore sought to examine the relationship of
this enzyme with the cytoskeleton in human PMN. When the
cellular proteins of PMN were separated into cytosolic and
cytoskeletal fractions using a Triton X-100 containing bu¡er
CSK according to the method reported earlier by the author
[39], an amount of Pyk2 was found associated with the cyto-
skeletal fraction (data not shown). We then immunoprecipi-
tated the kinase from the SDS-PAGE sample bu¡er lysates
of the cytoskeletal fraction and blotted for tyrosine phospho-
rylation of the molecules. As shown in the left three lanes in
the upper panel of Fig. 1B, an enhanced tyrosine phosphoryl-
ation of Pyk2 associated with the cytoskeletal fraction was
detected upon TNF or fMLP stimulation. When the mem-
brane was stripped and re-blotted for protein, comparable
amounts of Pyk2 protein were detected in each sample (lower
panel of Fig. 1B, as well as in the lower panels of other
¢gures), demonstrating that the di¡erence in tyrosine phos-
phorylation detected by anti-phosphotyrosine (PY) blotting
was not due to di¡erences in the amount of protein in each
precipitate.
3.2. Pyk2 phosphorylation induced by TNF or fMLP is
mediated by L2 integrin-dependent adhesion
The fact that tyrosine-phosphorylated Pyk2 was detected
when associated with the cytoskeletal fraction of human
PMN led us to anticipate that the activation of this enzyme
might be tightly related to cell adhesion [1]. We then com-
pared the phosphorylation of Pyk2 in cells adherent to ¢bri-
nogen and in suspension. Both TNF and fMLP induced Pyk2
tyrosine phosphorylation in adherent cells. Pyk2 phosphoryl-
ation was clearly evident after 5 min and gradually dephos-
phorylated thereafter (Fig. 2). The phosphorylation of Pyk2
was detectable even when the cells were incubated for as long
as 60 min on ¢brinogen (data not shown). In contrast, when
cells were incubated in suspension by shaking in tubes, neither
TNF nor fMLP triggered a detectable enhancement of tyro-
sine phosphorylation of the kinase (Fig. 2). These results were
con¢rmed by two di¡erent experimental methods: immuno-
precipitating with the anti-Pyk2 Ab followed by Western blot-
ting using anti-PY mAb PY20 (Fig. 2A upper panel) or im-
munoprecipitating with PY20 followed by Western blotting
using the anti-Pyk2 Ab (Fig. 2B). Both methods of detection
demonstrated similar results (Fig. 2). In both cases, similar
amounts of Pyk2 protein were assessed for tyrosine phospho-
rylation from adherent and non-adherent cells (Fig. 2A, lower
panel).
Because ¢brinogen is a well known ligand for L2 integrins
of PMN [1], the involvement of integrins in the induction of
Pyk2 phosphorylation following TNF or fMLP stimulation
was evaluated using speci¢c Abs to block selected integrin
activation. PMN were pre-treated with anti-integrin Abs prior
to plating on ¢brinogen-coated wells. As shown in Fig. 3A,
the anti-L2 chain integrin Ab IB4 and to a lesser extent an-
other anti-L2 chain integrin Ab L130 (Fig. 3B), but not the
anti-L3 chain integrin Ab SZ21 or control mouse IgG, atten-
uated the tyrosine phosphorylation of Pyk2 induced by TNF
or fMLP in PMN adherent to ¢brinogen. Blocking of the L1
chain integrin with a mAb Lia1/2 (Immunotech, Westbrook,
ME, USA) showed no inhibitory e¡ect on Pyk2 phosphoryl-
ation in ¢brinogen adherent cells (data not shown). Similar to
our previous observations of the activation of src-like kinases
by TNF in ¢brinogen adherent PMN [10], the K-chains of L2
integrins were not involved in the TNF- or fMLP-stimulated
phosphorylation of Pyk2 in PMN adherent to ¢brinogen since
Fig. 2. Stimulation of Pyk2 phosphorylation by TNF and fMLP in
human PMN is adhesion-dependent. PMN were incubated in ¢bri-
nogen-coated wells (adherent) or shaking tubes (suspension) in the
absence or presence of TNF or fMLP for the indicated time and cy-
toskeletal fractions were prepared from these cells as described in
the legend to Fig. 1B. The immunoprecipitation (IP) was performed
using Abs anti-Pyk2 (A) or anti-phosphotyrosine (PY) (B) and the
Western blotting (WB) was done using the method described in the
legend to Fig. 1B for A and that described in Fig. 1A for B. This
¢gure represents one of four experiments with similar results.
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pre-blocking of CD11a, CD11b or CD11c with mAbs G25.2,
D12 and SHCL-3, respectively, failed to inhibit the phospho-
rylation of the kinase induced by fMLP (Fig. 3B) or TNF
(data not shown). These data suggest that the activation of
Pyk2 by TNF and fMLP in human PMN is a L2 integrin-
dependent event.
3.3. Phosphorylation of Pyk2 is a downstream event of the
activation of p53/56lyn, p72syk, PKC and cytoskeletal
rearrangement
As addressed above, integrin signaling can activate PTKs,
PI-3 kinase and cytoskeletal rearrangement [3]. In addition,
the phosphorylation of Pyk2 appears to be associated with L2
integrin activation. Therefore, we sought to further character-
ize the signaling pathway which links L2 integrin activation to
Pyk2 phosphorylation using some speci¢c inhibitors. When
PMN were treated with the tyrosine kinase inhibitor genistein
(50 WM) for 10 min before the addition of stimuli, the en-
hanced tyrosine phosphorylation of Pyk2 induced by TNF
or fMLP was mostly attenuated (Fig. 4A and data not
shown). It was not certain if this was due to the direct e¡ect
of genistein on this kinase or due to the inhibition of other
PTKs, especially those of the src family, since genistein inhib-
its mainly src-like kinases. We then introduced a highly spe-
ci¢c inhibitor (PP1) of src family PTKs which we have pre-
viously demonstrated to be highly speci¢c for p53/56lyn in
human PMN [14]. The inhibition of p53/56lyn with PP1 gave
rise to a similar decrease in tyrosine phosphorylation of Pyk2
induced by TNF or fMLP (Fig. 4A) to that observed in gen-
istein-treated cells, indicating that Pyk2 may be downstream
of p53/56/lyn. Nevertheless, it should be noted that neither
genistein nor PP1 could completely abolish the phosphoryla-
tion of Pyk2 (Fig. 4A), suggesting that there may be signaling
pathway(s) other than src family kinases which can lead to the
activation of Pyk2. Actually, the activation of p72syk and the
rearrangement of the cytoskeleton may play a more important
role in TNF or fMLP-induced phosphorylation of Pyk2. In
PMN treated with piceatannol (5 WM), a speci¢c inhibitor for
p72syk [7,14], or cytochalasin B (5 Wg/ml), which blocks actin-
based cytoskeleton polymerization, the phosphorylation of
Pyk2 was almost completely abolished (Fig. 4A and data
not shown). As with other cell lines [22,28,30,31,44], the ac-
tivity of PKC is involved in the activation of Pyk2 in human
PMN since treatment of the cells with PKC inhibitors Go«6850
or staurosporine caused a profound inhibition of Pyk2 phos-
phorylation stimulated by TNF or fMLP (Fig. 4B and data
Fig. 3. Stimulation of tyrosine phosphorylation of Pyk2 by TNF
and fMLP in human PMN adherent to ¢brinogen is L2 integrin-de-
pendent. PMN were pre-incubated with 10 Wg/ml of either normal
mouse IgG (mIgG), IB4 (anti-CD18, the L2 integrin L-chain), SZ21
(anti-CD61, the L3 integrin L-chain), G25.2 (anti-CD11a), D12
(anti-CD11b), SHCL-3 (SHCL, anti-CD11c) or L130 (anti-CD18)
for 45 min on ice before they were incubated in ¢brinogen-coated
wells. After being stimulated without or with TNF or fMLP for
5 min, the cytoskeletal fractions of the cells were prepared and
Pyk2 was immunoprecipitated (IP) and analyzed by Western blot-
ting (WB) as described in the legend to Fig. 1B. This ¢gure repre-
sents one of three experiments with similar results.
Fig. 4. Src and Syk tyrosine kinases and PKC as well as actin po-
lymerization are involved in the induction of Pyk2 phosphorylation
by TNF and fMLP in human PMN adherent to ¢brinogen. PMN
were pretreated with the solvent (DMSO) or inhibitors for PTKs
(genistein or Gen.), src kinases (PP1), syk kinase (piceatannol or
Pic.), PKC (bisindolylmaleimide I or Bisin.), PI-3 kinase (wortman-
nin or Wort.) or actin polymerization (cytochalasin B or CB) for
10 min at 37‡C in ¢brinogen-coated wells before stimulating without
or with TNF or fMLP for 5 min. The SDS-PAGE sample bu¡er ly-
sates of the cytoskeletal fractions were immunoprecipitated (IP) us-
ing anti-Pyk2 (A) or anti-PY (B) Abs and analyzed by Western
blotting (WB) using HRP-PY20 (A) or anti-Pyk2 (B) as described
in the legends to Fig. 1 and Fig. 2. This ¢gure represents one of
three experiments with similar results.
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not shown). Direct activation of PKC by phorbol 12-myris-
tate 13-acetate (PMA) triggered a more intense tyrosine phos-
phorylation of Pyk2 in comparison to stimulation by TNF or
fMLP (data not shown). The PI-3 kinase signaling pathway,
although associated with Pyk2 in THP1 cells [29], is not nec-
essary for Pyk2 activation in PMN. As shown in Fig. 4B,
inhibition of PI-3 kinase with wortmannin a¡ected neither
TNF nor fMLP-induced tyrosine phosphorylation of Pyk2
in human PMN adherent to ¢brinogen.
4. Discussion
These studies indicated that Pyk2 was present in human
PMN and was tyrosine-phosphorylated after cell stimulation
with TNFK or fMLP. The induction of Pyk2 phosphorylation
by these stimuli in PMN was dependent on cell adhesion to
¢brinogen and was mediated by L2 integrins. Activation of src
family kinases (p53/56lyn), syk family kinases (p72syk), PKC
and cytoskeletal rearrangement, all important downstream
events of integrin signaling, were important in the phospho-
rylation of Pyk2 in PMN. More notably, the phosphorylated
Pyk2 was mainly found associated with a Triton X-100 in-
soluble cytoskeletal fraction. These results strongly suggest
that the tyrosine phosphorylation and activation of Pyk2 in
PMN may play a role in the regulation of adhesion/cytoske-
leton-associated PMN functions.
TNF and fMLP bind through distinct receptors and there-
fore, their signaling pathways should be di¡erent. Actually,
they activate PMN in very distinct ways. In vitro, the opti-
mum activation of PMN function by TNF can only be
achieved when the cells are allowed to adhere to certain sur-
faces [1]. When the cells are incubated in suspension, TNF
mainly acts to prime the cells [45,46]. In contrast, fMLP can
activate PMN when adherent and in suspension [1]. In vivo,
while fMLP induces PMN to migrate (chemotaxis), TNF im-
mobilizes PMN by activating cell adhesion [47,48]. When we
tried to assess the activation of Pyk2 in human PMN by these
two activators, we found unexpectedly that these contradic-
tory pathways of PMN activation induced Pyk2 phosphoryl-
ation in a very similar manner: similar in time-course, in
cytoskeletal association and in L2 integrin-dependence as
well as in the sensitivity to inhibitors for PTKs, src family
kinases, p72syk, PKC and cytoskeleton polymerization. It ap-
pears that there must be a mechanism which is shared by the
two stimuli that leads to the activation of Pyk2.
Pyk2 belongs to the FAK family and, like its homolog
FAK, localizes to sites of cell to cell contact and to focal
adhesion-like structures [23,27]. At these sites, some structural
and signaling molecules form focal adhesion complexes that
contain cytoskeletal proteins such as talin, vinculin, K-actinin,
¢lamin, FAK and other phosphoproteins [3,27,49]. Although
PMN do not form classical focal adhesion complexes, integrin
activation results in tyrosine phosphorylation of several pro-
teins and the formation of focal adhesion-like structures [50].
Here, we observed that the stimulated tyrosine phosphoryla-
tion of Pyk2 was dependent on the adhesion of PMN to
¢brinogen (Fig. 2). Therefore, cell adhesion may serve as a
key step in the activation of Pyk2 in human PMN. It should
be noted that both TNF and fMLP are powerful activators of
PMN adhesion [1]. Their e¡ects on the stimulation of Pyk2
phosphorylation may be achieved through their activation of
PMN adhesion even though in other cell systems, stimulation
by G-protein-coupled receptors (such as fMLP) results in the
tyrosine phosphorylation of Pyk2 [22,24,26,28].
Adhesion of human PMN to ¢brinogen has been demon-
strated to be mediated by L2 integrins [1] and therefore, L2
integrin signaling may account for Pyk2 phosphorylation. It
has been shown that the aggregation of L1 integrins in B-cells
and L3 integrins in T-cells results in tyrosine phosphorylation
of Pyk2 [35,36]. We herein provide evidence that the phos-
phorylation of Pyk2 in human PMN adherent to ¢brinogen in
response to stimulation by TNF or fMLP is a function of L2
integrin ligation since it is attenuated by L2 integrin blocking
(Fig. 3). After appropriate activation, integrins can generate
intracellular signals which rapidly induce the activation of
several signaling pathways including the activation of PTKs
(especially those of the src family and syk family), of PKC
and of actin polymerization [1,3]. Hence, it is not surprising to
note that, as with the results obtained from other cell lines
[22,28,30^32,34,44,51,52], the activities of src-like kinases (es-
pecially p53/56lyn), syk kinase p72syk, PKC and cytoskeletal
rearrangement are all involved in the induction of Pyk2 phos-
phorylation, in human PMN.
The biological function of Pyk2 in distinct cell lines is still
unclear. This enzyme has been reported to interact with sig-
naling molecules such as paxillin [42,43], Grb2 [22,33] and
p130cas [36]. Although src family kinases such as Fyn, Lck
and c-Src associate by their SH2 domains with Pyk2 [26,33],
we could not detect association of Pyk2 with the src-like kin-
ases p53/56lyn, p58cÿfgr and p59hck during immunoprecipita-
tion experiments (data not shown). Pyk2 tyrosine phospho-
rylates the potassium channel and suppresses channel currents
[22] and also acts as an upstream regulator for stress signal
activation of c-Jun N-terminal kinase [25]. As many of these
pathways are activated in stimulated PMN [2], tyrosine phos-
phorylation of Pyk2 may play an important role in signal
transduction and cell function.
In summary, these experiments indicate that stimulation of
PMN with TNF and fMLP induces the tyrosine phosphoryl-
ation of Pyk2 which is dependent on cell adhesion. The phos-
phorylated Pyk2 is mainly associated with a Triton X-100
insoluble cytoskeletal fraction. The activation of p53/56lyn,
p72syk and PKC by L2 integrin signaling appears to be in-
volved in the phosphorylation of Pyk2 in human PMN adher-
ent to ¢brinogen. Pyk2 may therefore play a role in the reg-
ulation of adhesion/cytoskeleton-associated PMN function.
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